UPDATE 3-U.S. top court rejects Amgen over cholesterol medication patent fight [Reuters]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Reuters
U.S. top court rejects Amgen over cholesterol medication patent fight WASHINGTON (Reuters) - Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. The justices declined to hear Amgen’s appeal seeking reinstatement of a jury verdict it won against Regeneron and Sanofi in the dispute in which Amgen accused its rivals of infringing its patents relating to its competing drug Repatha and sought to block sales of Praluent. Amgen had asked the justices to overturn a 2017 decision by the U.S. Court of Appeals for the Federal Circuit that set aside the jury’s verdict, nullified a ban imposed by a judge on Praluent sales and ordered a new trial. The sales ban was put on hold while the matter was on appeal, never taking effect. Sanofi and Regeneron said in a joint statement they were
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at UBS Group AG from $314.00 to $284.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at TD Cowen from $370.00 to $360.00. They now have a "buy" rating on the stock.MarketBeat
- Can This High-Yield Dividend Stock Keep Beating the S&P 500? [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- 4/10/24 - Form ARS
- AMGN's page on the SEC website